Table 2.

Association of baseline characteristics and clinical outcomes

CharacteristicNo.OSDFSRelapseNRM
HR*95% CIP*HR*95% CIP*HR95% CIPHR95% CIP
Age at diagnosis, y
 <5555Ref.71Ref.96Ref.32Ref.48
 55-65431.200.62-2.310.920.50-1.690.510.18-1.431.470.66-3.25
 >65121.460.54-3.920.970.37-2.540.380.05-3.041.760.62-5.00
Age at allo-HCT, y
 <5538Ref.24Ref.88Ref.30Ref.14
 55-65511.600.77-3.331.130.59-2.160.460.16-1.282.360.90-6.16
 >65212.030.83-4.951.220.53-2.810.560.16-2.002.370.75-7.44
Years from diagnosis to HCT
 <147Ref.71Ref.60Ref.63Ref.63
 1 to <3290.720.33-1.580.710.35-1.460.860.29-2.540.650.25-1.72
 3+340.910.45-1.870.800.40-1.570.570.18-1.811.000.44-2.26
Sex
 Male65Ref.071Ref.065Ref.20Ref.26
 Female450.540.28-1.070.560.30-1.050.520.19-1.450.640.29-1.41
Year of allo-HCT
 2004-201156Ref.71Ref.53Ref.41Ref.98
 2012-2017541.120.58-2.170.830.45-1.540.670.26-1.700.920.43-1.97
Female donor to male recipient
 Yes18Ref.23Ref.53Ref.97Ref.47
 No920.640.30-1.350.790.38-1.650.970.28-3.350.720.31-1.70
ABO compatibility
 Compatible61Ref.61Ref.97Ref.50Ref.52
 Minor180.850.32-2.261.080.47-2.522.020.68-5.940.440.10-1.88
 Major201.510.69-3.281.170.55-2.511.010.28-3.681.220.48-3.08
 Bidirectional111.440.54-3.851.170.45-3.060.570.08-4.291.560.53-4.59
Donor type
 Related51Ref.001Ref.002Ref.12Ref<.001
 MUD 10/10441.460.72-2.952.351.21-4.552.330.87-6.211.770.76-4.14
 <10/10153.961.76-8.883.641.63-8.150.570.07-4.905.642.20-14.45
DIPSS classification at allo-HCT
 Low-intermediate-126Ref.023Ref.035Ref.16Ref.22
 Intermediate-2 to high832.601.09-6.182.181.01-4.702.690.62-11.661.650.70-3.91
Recipient CMV
 Negative19Ref.46Ref.89Ref.98Ref.86
 Positive911.390.58-3.301.060.49-2.261.020.29-3.551.070.41-2.83
Donor CMV
 Negative49Ref.25Ref.18Ref.65Ref.28
 Positive600.700.38-1.300.680.38-1.210.810.32-2.020.700.34-1.43
KPS
 90-10046Ref.36Ref.43Ref.057Ref.65
 70-80371.450.71-2.941.390.70-2.771.950.56-6.781.070.46-2.48
 Unknown270.860.37-1.971.540.75-3.173.961.21-12.990.740.29-1.88
HCT-CI
 038Ref.59Ref.41Ref.085Ref.73
 1261.480.65-3.371.470.65-3.331.970.45-8.601.200.46-3.13
 2211.510.61-3.731.680.71-3.981.890.38-9.331.430.51-4.04
 Unknown250.960.40-2.281.850.85-4.024.701.25-17.600.880.33-2.38
MF
 Primary58Ref.29Ref.13Ref.77Ref.19
 Secondary520.720.39-1.340.640.36-1.150.870.35-2.190.610.29-1.27
Ruxolitinib use
 No78Ref.33Ref.96Ref.26Ref.35
 Yes321.390.68-2.860.980.49-1.960.490.14-1.731.400.61-3.22
Splenectomy before HCT
 No94Ref.24Ref.82Ref.015Ref.062
 Yes160.580.23-1.501.090.50-2.373.311.28-8.600.310.07-1.38
Cytogenetics
 Favorable67Ref.006Ref.004Ref.035Ref.23
 Unfavorable241.800.84-3.861.290.62-2.690.540.12-2.461.800.75-4.34
 VHR153.111.48-6.533.001.49-6.042.951.11-7.821.990.81-4.90
  • HCT-CI, hematopoietic cell transplantation–specific comorbidity index; KPS, Karnofsky performance status; Ref, reference.

  • * Based on univariable analysis and log-rank test.

  • Based on cumulative incidence accounting for competing risks and Gray test.